IRCT20200105046010N25招募中未知
In- Vivo Bioequivalence study of Teriflunomide tablet 14 mg Aburayhan Pharma with brand drug (AUBAGIO® 14 mg Genzyme, Germany) in Iranian healthy volunteers.
Aburayhan Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Teriflunomide tablets with brand drug (AUBAGIO® 14 mg, Genzyme, Germany)Bio equivalence test.IRCT20200105046010N47Abidi Pharmaceutical Company24
招募中
3 期
The safety and effect of Teriflunomide in patients with HTLV-1-induced myelopathyIRCT20180618040127N3Mashhad University of Medical Sciences22
招募中
不适用
In-vivo Bioequivalence study of Rhofinib tablet with brand drugs (XELJANZ® 10 mg, Pfizer, Ireland)IRCT20200105046010N38anoalvand Pharmaceutical Co24
招募中
不适用
In-vivo Bioequivalence study of Tadalafil tablet with brand drugs (CIALIS Lilly USA)IRCT20200105046010N39Mofid Pharmaceutical Co.24
已完成
3 期
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisMultiple SclerosisNCT02201108Genzyme, a Sanofi Company166